Cancer/Vaccine

Melanoma Vaccine Improves Survival in Patients with Antibody Response

Published in Vaccine Weekly, February 27th, 1995

New York University School of Medicine researchers find that the antibody response to a polyvalent melanoma antigen vaccine is predictive of a later reduction in the recurrence of melanoma.

Kenneth Miller et al. investigated the clinical relevance of antibody responses to melanoma vaccine immunization in 108 patients with surgically resected, stage III malignant melanoma ("Improved Survival of Patients with Melanoma with an Antibody Response to Immunization to a Polyvalent Melanoma Vaccine," Cancer, January 15, 1995;75(2):495-502).

"The study was conducted with a polyvalent melanoma antigen vaccine constructed from surface material shed into culture...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1995-02-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry